drugset / Trial / NCT06391034
Magnetic Resonance (MR) Imaging With Hyperpolarized 13C-Pyruvate +/- 13C,15N-Urea in Patients With Prostate Cancer
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This is a Phase 2 clinical study of hyperpolarized (HP) 13C-pyruvate (13C), 15N-urea (13C,15N) metabolic MR imaging in prostate cancer patients who are undergoing or have received radiation therapy for prostate cancer.
Timeline
- Start
- 2024-09-24
- Primary completion
- 2028-12-31
- Completion
- 2032-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hyperpolarized Pyruvate | Diagnostic / imaging agent | — | Intravenous |
| Subject | urea | Unknown | — | Intravenous |